| __timestamp | Amphastar Pharmaceuticals, Inc. | Biogen Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 2232342000 |
| Thursday, January 1, 2015 | 46974000 | 2113100000 |
| Friday, January 1, 2016 | 47298000 | 1947900000 |
| Sunday, January 1, 2017 | 50918000 | 1935500000 |
| Monday, January 1, 2018 | 58044000 | 2106300000 |
| Tuesday, January 1, 2019 | 63109000 | 2374700000 |
| Wednesday, January 1, 2020 | 65157000 | 2504500000 |
| Friday, January 1, 2021 | 68920000 | 2674300000 |
| Saturday, January 1, 2022 | 66592000 | 2403600000 |
| Sunday, January 1, 2023 | 80393000 | 2549700000 |
| Monday, January 1, 2024 | 2403700000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. Over the past decade, Biogen Inc. and Amphastar Pharmaceuticals, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Biogen's SG&A expenses have consistently dwarfed those of Amphastar, averaging nearly 40 times higher. This stark difference highlights Biogen's expansive operational scale and market reach.
Amphastar, on the other hand, has shown a steady increase in SG&A expenses, peaking in 2023 with a 99% rise from 2014. This growth reflects Amphastar's strategic investments in expanding its market presence. Meanwhile, Biogen's SG&A expenses peaked in 2021, indicating a potential shift towards optimizing operational costs. As the pharmaceutical landscape continues to evolve, these trends offer valuable insights into the strategic priorities of these industry players.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Biogen Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Biogen Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Biogen Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Biogen Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Alkermes plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.